"AAN: Novel Drugs Ease Troubling PD Symptoms" - John Gever
An adenosine 2-alpha receptor antagonist called tozadenant reduced so-called "off time" without promoting dyskinesias, according to C. Warren Olanow, MD, of the Icahn School of Medicine at Mount Sinai in research presented at the American Academy of Neurology annual meeting. In the phase II trial conducted by Dr. Olanow and colleagues, 420 patients were randomized to placebo or one of four doses of tozadenant for 12 weeks in addition to stable doses of levodopa. All patients were showing at least 2.5 hours of off time—when the medication wears off—daily at enrollment. Tozadenant showed significant decreases in off time when measured at week 12.
-Dr. C. Warren Olanow, Professor and Chair Emeritus, Neurology, Professor of Neuroscience, The Icahn School of Medicine at Mount Sinai
Mount Sinai Launches AI Small Molecule Drug Discovery Center
Apr 02, 2025 View All Press Releases
Mount Sinai Launches Institute for Regenerative Medicine
Apr 24, 2023 View All Press Releases
